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bacterial membrane vesicles of non-typeable Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and Pseudomonas aeruginosa.
Editor: David Clarke
†Frank R.M. Stassen, http://orcid.org/0000-0003-3710-0948
ABSTRACT
Bacterial infections contribute to the disease progression of chronic obstructive pulmonary disease e.g. by stimulating
mucus production in the airways. This increased mucus production and other symptoms are often alleviated when patients
are treated with mucolytics such as N-acetyl-L-cysteine (NAC). Moreover, NAC has been suggested to inhibit bacterial
growth. Bacteria can release membrane vesicles (MVs) in response to stress, and recent studies report a role for these
proinflammatory MVs in the pathogenesis of airways disease. Yet, until now it is not clear whether NAC also affects
the release of these MVs. This study set out to determine whether NAC, at concentrations reached during high-dose
nebulization, affects bacterial growth and MV release of the respiratory pathogens non-typeable Haemophilus influenzae
(NTHi), Moraxella catarrhalis (Mrc), Streptococcus pneumoniae (Spn) and Pseudomonas aeruginosa (Psa). We observed that NAC
exerted a strong bacteriostatic effect, but also induced the release of proinflammatory MVs by NTHi, Mrc and Psa, but not by
Spn. Interestingly, NAC also markedly blunted the release of TNF-α by naive macrophages in response to MVs. This suggests
that the application of NAC by nebulization at a high dosage may be beneficial for patients with airway conditions
associated with bacterial infections.
Keywords: membrane vesicles; N-acetyl-L-cysteine; non-typeable Haemophilus influenzae; Moraxella catarrhalis; Streptococcus
pneumoniae; Pseudomonas aeruginosa
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a respira-
tory condition that poses a huge burden on the society world-
wide (Pauwels 2001; Lopez et al. 2006). Patients with COPD of-
ten show an increased mucus production, sputum purulence
and cough (Hauber, Foley and Hamid 2006; Miravitlles 2011;
Montes De Oca et al. 2012). To alleviate symptoms, mucolytics
are frequently prescribed (van Overveld et al. 2005; Poole 2006;
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Sadowska et al. 2006; Poole, Chong and Cates 2015). A commonly
administered mucolytic is N-acetyl-L-cysteine (NAC): a small
thiol-containing antioxidant that acts by disrupting disulphide
bonds in mucus (Sheffner 1963; Poole 2006). Two recent meta-
analyses concluded that patients with COPD experience less ex-
acerbations after oral NAC administration (Cazzola et al. 2015;
Poole, Chong and Cates 2015).
Bacterial respiratory infections are the main cause of exac-
erbations in patients with COPD and bacteria also have been
shown to contribute the progression of stable disease (Sethi and
Murphy 2008; Marin et al. 2012; King, MacDonald and Bardin
2013; Desai et al. 2014). A variety of studies have shown that NAC
does not only have anti-oxidant or anti-inflammatory charac-
teristics, but also bacteriostatic properties (Parry and Neu 1977;
Riise et al. 2000; Olofsson, Hermansson and Elwing 2003; Huynh
et al. 2004; Zhao and Liu 2010). These bacteriostatic effects of
NAC are thought to be mediated by the inhibition of cysteine
utilization by bacteria (Parry and Neu 1977). It is now understood
that cysteine deprivation, besides its bacteriostatic action, also
induces a bacterial stress response which is characterized by
the release of bacterial membrane vesicles (MVs) (van deWater-
beemd et al. 2013). MVs carry several bacterial virulence factors
causing them to exert strong proinflammatory responses (as re-
viewed in Brown et al. 2015; Schwechheimer and Kuehn 2015).
Therefore, in this study we examined the effect of NAC
on both the MV release and growth of the common respi-
ratory pathogens non-typeable Haemophilus influenzae, (NTHi),
Moraxella catarrhalis (Mrc), Streptococcus pneumoniae (Spn) and
Pseudomonas aeruginosa (Psa). Moreover, we determined if NAC
affects the MV-induced proinflammatory responses.
MATERIALS AND METHODS
Reagents and antibodies
NAC (Sigma, St. Louis, MO, USA) was dissolved at 200 mM and
the pH was corrected to 7.0–8.0. Antibodies against CD63 (un-
conjugated, mouse-anti-human clone H5C6) and CD81 (PE con-
jugated, mouse-anti-human clone JS-81) were obtained from BD
(BD Bioscience, Franklin Lakes, NJ, USA). The anti-Haemophilus
influenzae type b (α-Hib; clone 1079/457) monoclonal antibody
was obtained from Acris (Acris GmbH, Herford, Germany).
The rabbit serum against Mrc (strain A 1.39N, isolated from
children in a primary school in Nieuwegein, the Netherlands
(1989)), was kindly provided by Dr J. Hays (Erasmus University,
Rotterdam, theNetherlands). The antibody against Psawas from
Antibodies online (Aviva Systems Biology, San Diego, CA, USA,
neat raised in guinea pig). Antibodies were purified using the
antibody serum purification kit based on protein A (Abcam,
Cambridge, MA, USA). For flow cytometric analysis, detec-
tion antibodies were PE conjugated using PE-labeling kits from
Abcam. One hundred microgram of each antibody was PE con-
jugated according to the manufacturers’ instructions.
Bacterial strains and culturing
The following bacterial strains were used: NTHi (ATCC-49247),
Psa (ATCC-27853), Spn (ATCC-49619) and a Mrc clinical isolate
(University Medical Centre Maastricht (MUMC+), the Nether-
lands). Mrc, Spn and Psa were pre-cultured on blood plates,
and NTHi was cultured on vitalex-supplemented chocolate agar
plates (Oxoid, Wesel, Germany) overnight at 5% CO2 and 37◦C.
After overnight pre-culture, bacterial suspensionswith a density
of 0.5 McFarland (1.5 × 108 colony forming units (cfu)/ml) were
prepared. These suspensions were then used to prepare bacte-
rial cultures or for infection experiments. Bacteria were cultured
at 5 × 107 cfu/ml with or without NAC (5, 25 or 50 mM) for 6
h in 10 ml RPMI1640. NTHi and Mrc were cultured in medium
supplied with 10 μg/ml hemin and nicotinamide adenine dinu-
cleotide (both from Sigma). After 6 h, cultures were centrifuged
at 1200 × g for 10 min, at room temperature. The pelleted bac-
teria were washed, diluted in phosphate-buffered saline (PBS)
and the optical density was determined at 600 nm in optical
methacrylate disposable cuvettes (Sarstedt, Newton, NC, USA).
The supernatant was again centrifuged at 1200 × g for 10 min to
deplete possible remnant bacteria, followed by filtering the su-
pernatants through 0.22 μm filters. To allow MV quantification
by tunable resistive pulse sensing, supernatants were concen-
trated 20 times to a final volume of 500 μl by centrifugation at
4000 × g for 15 min using Amicon ultra-15 10-kDa centrifugal
filter units (Millipore, Billerica, MA, USA).
Bacterial MVs for the stimulation experiments were obtained
from bacteria that were cultured for 4 h in 30 ml complete
vesicle-depletedmedium (prepared as described in the cells and
media section) at a density of 1 × 108 cfu/ml. Upon culture, su-
pernatants were depleted from bacteria by two centrifugation
steps at 1200× g for 10min and 0.22μmfiltration. Cleared super-
natants were then further processed by ultrafiltration and size-
exclusion chromatography (SEC), as described below.
Cells and media
Human monocytic THP-1 cells (ATCC-TIB202) were cultured
at 5% CO2 and 37◦C in RPMI1640 (Sigma) containing 10% fe-
tal calf serum (FCS) (Lonza, Verviers, Belgium) with glucose
(22.5%), sodium pyruvate (100 mM) and β-mercaptoethanol (25
mM). Monocytes, seeded at 0.5 × 106 cells per well in 24-
wells plates, 1 × 104 per well in 96-wells plates and 1 × 107
cells in T75-flasks, were differentiated using 200 nM phorbol
12-myristate 13-acetate (PMA; Sigma) for 72 h. Hereafter, the
medium was replaced with vesicle-depleted culture medium
containing 5% FCS containing glucose (22.5%), and sodium pyru-
vate (100 mM), hereafter referred to complete vesicle-depleted
medium. Medium with 30% FCS was depleted from abundant
and possibly confounding bovine MVs by combining FCS-free
culture medium with vesicle-depleted medium with 30% FCS.
Vesicle-depleted medium with 30% FCS was obtained by the
overnight centrifugation at 100 000 × g using a 70Ti-rotor, κ-
factor 44 in an Optima L-90K ultracentrifuge (both Beckman
Coulter, Fullerton, CA, USA).
Infection of macrophages for MV analysis
For macrophage infections in 24-wells plates, cells were washed
three times with PBS whereafter the medium was replaced
with complete vesicle-depleted culture medium. Hereupon,
macrophages were infected with either one of the bacteria at a
multiplicity of infection of 10. After 6 h of infection, the medium
was harvested, processed by two centrifugation steps at 1200 ×
g for 10min and 0.22 μmfiltration, and used for bead-based flow
cytometry.
MV concentration and purification from conditioned
medium using ultrafiltration and SEC
MVs were concentrated from bacteria-cleared supernatants
by using ultrafiltration (Lobb et al. 2015) and separated from
protein by SEC (Böing et al. 2014). This method for vesicle
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isolation is considered one of the most appropriate methods for
the isolation of verwijderen?/mammalian extracellular vesicles
as it provides with an efficient standardizedmethod for the gen-
eration of pure intactMVpopulations (Böing et al. 2014; Lobb et al.
2015; Nordin et al. 2015). For ultrafiltration, the cleared super-
natants were concentrated 60 times to 500 μl in two centrifu-
gation runs at 4000 × g for 15 min at room temperature using
Amicon ultra-15 10-kDa centrifugal filter units (Millipore). The
method for MV purification by SEC was performed as previously
described by Böing et al. (2014), with minor alterations. Briefly,
a 15 ml-TELOS filtration column (Kinesis Scientific Experts, St.
Neots, Cambridgeshire, UK) was stacked with 10 ml sepharose
CL-2B (GE Healthcare, Uppsala, Sweden). Next, the concentrates
were loaded onto the column and eluted using PBS. Twenty-four
fractions of 500 μl were collected and the MV-containing frac-
tion (based on five pooled fractions: 7–11, previously identified
to be highly enriched for MVs and negative for free proteins) was
stored at –80◦C until further use.
MV analysis by tunable resistive pulse sensing
The MV concentration was determined by tunable resistive
pulse sensing using the qNano Gold, the Izon Control Suite Soft-
ware v3.2 and the reagent kit (type RK1) for EV analysis from Izon
(Izon Science Ltd, Oxford, UK). Measurements were conducted
using a NP150 pore with a fixed stretch of 47 mm, a transmem-
brane voltage of 0.48 V (led to a baseline current of ±100 nA) and
a pressure of 6mbar. SolutionGwas added (10%) to supernatants
that were diluted in solution Q (1:1) and each sample was mea-
sured for 10min andmeasurementswere repeatedwhen system
instabilities occurred. The sampleswere calibrated using 114 nm
polystyrene calibration beads (CPC100, Izon Science Ltd.) at a
concentration of 1 × 109 particles/ml diluted in culture medium.
Flow cytometric analysis of MVs using antibody-coated
latex beads
Bead-based flow cytometry was used for the semiquantita-
tive analysis of MVs released by macrophages and bacteria.
This method was previously described (Ostrowski et al. 2010;
Kapustin et al. 2015) and was adopted for bacterial vesicle
quantification (Volgers et al. 2017). Briefly, 4-μm-sized aldehyde-
sulfate beads were washed in MES buffer and coated with anti-
CD63 for host-cell vesicles or with an antibody against one of the
bacterial MVs. Antibody-coated beads were incubated overnight
with 200 μl of cleared supernatant under constant agitation at
1000 rpm at room temperature. Next, the beads were washed
twice with 0.22 μm filtered PBS with 2% (w/v) bovine serum al-
bumin and incubated with a PE-conjugated detection antibody,
for 90min at room temperature under continuous agitation. An-
tibacterial antibodies were PE conjugated using a PE conjugation
kit (Abcam) following the manufacturer’s instructions and for
the host-cell MVs, the detection was based on anti-CD81-PE la-
beled detection antibodies. After incubation with the PE-labeled
detection antibodies, the beads were washed and suspended in
300 μl PBS for flow cytometric analysis on a FACSCanto (BD Bio-
science, Franklin Lakes, NJ, USA). The lower threshold for de-
tection was set at 2% based on the percentage of PE-positive
control beads (incubated with unconditioned culture medium).
Analyses were performed using FACSDiva Software. The relative
amount of MVs was calculated by the multiplication of the per-
centage of positive beads with the median fluorescence inten-
sity and expressed relative to the control (as % of control).
Macrophage stimulation with MVs
Stimulation of macrophages with MVs was performed using
macrophages seeded in 96-well plates. Prior to stimulation,
macrophages in 96-well plates were washed three times with
PBS after the medium was replaced with vesicle-depleted cul-
ture medium with 5% FCS. Then, cells were exposed to 20 μl
of the MV-containing SEC fraction for 16 h, without or in
the presence of NAC (5 μM, 5 mM or 25 mM). Hereafter, the
culture supernatants were harvested and used for cytokine
measurements.
Assessment of the bacterial growth and adhesion and
internalization
To assess for bacterial growth during culture, the optical den-
sity at 600 nm was determined at a path length of 1 cm using
a spectrophotometer (Novaspec II: Pharmacia Biotech, Uppsala,
Sweden) (Sutton 2011). PMA-stimulated monocytes seeded in
24-well plates were washed three times with PBS after which
vesicle-depleted culture medium was added. Next, the cells
were infected with either one of the bacteria at an MOI of 10
for 4 h. After infection, the media were collected to assess bac-
terial survival (and for flow cytometric analysis of bacterial and
host-cell MV release). To assess bacterial survival, bacteria were
pelleted by centrifugation at 1200 × g, resuspended in 1 ml PBS,
whereupon bacterial dilutions were made and plated. In addi-
tion to bacterial survival, bacterial adhesion and internalization
were determined. After the supernatant was harvested, cells
were washed three times with PBS and lysed by adding 0.025%
saponin in distilled water for 10 min. After neutralization, by
the addition of culture medium, bacterial adhesion and inter-
nalization were determined by bacterial plating. The number of
adhered and internalized bacteria was then determined by
counting.
Cytokine measurements
The human Ready-Set-Go TNF-α enzyme-linked immunosor-
bent assay kit (Affymetrix eBioscience, Santa Clara, CA, USA)
was used to determine the TNF-α release according to the man-
ufacturer’s instructions.
Statistical analyses
Statistical analysiswas performedusingGraph-Pad Prism5 Soft-
ware (Graph-Pad, San Diego, CA, USA). Statistical dispersion was
determined by calculation of the standard error of the mean. A
Mann-Whitney t-test was performed for the statistical analysis
of the variance between themeans of two groups. P-values were
considered significant when <0.05.
RESULTS
The effect of NAC on bacterial growth
First, it was determined whether NAC affects the growth of the
common respiratory pathogens NTHi, Mrc, Spn and Psa. We ini-
tially determined if the growth was affected by NAC concen-
trations of 5–50 mM, a concentration based on the estimated
concentration of ∼30 mM that may be achieved in the lower
airway upon administration of 300 mg NAC by nebulization
and which may therefore be physiologically relevant (Szkud-
larek et al. 2004). As shown in Fig. 1, in the presence of 50 mM
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Figure 1. Bacterial growth and MV release by respiratory pathogens during bac-
terial culture with or without NAC. NTHi, Mrc, Spn and Psa were cultured for
6 h without or in the presence of NAC (5, 25 or 50 mM). Bacterial growth was
determined with the optical density of the bacterial suspensions at 600 nm (A).
Additionally, the MV release was determined by tunable resistive pulse sens-
ing (B) and the MV release was adjusted for the number of bacteria (C). All val-
ues are presented here as percentage of the untreated control condition. (n = 3,
∗P < 0.05).
NAC bacterial growth was reduced by 43%, 66%, and 80% of the
Gram-negative bacteria NTHi, Mrc, and Psa, respectively. Finally,
the bacterial growth of the Gram-positive Spn was also reduced
by 47%.
Bacterial MV release in response to NAC
Next, the effect of NAC on the release of bacterial MVs was as-
sessed by tunable resistive pulse sensing-based analysis. We ob-
served that the addition of NAC at a concentration of 5 mM
resulted in a 2-fold and 3-fold increase in the release of NTHi
and Mrc MVs, respectively (Fig. 1B). This MV release was also
increased after treatment with higher concentrations, albeit
to a lesser extent. Yet, since NAC markedly inhibited bacte-
rial growth (Fig. 1A), we adjusted the release of MVs for the
number of bacteria present in each culture condition. After
adjustment, the bacterial MV release was found to be increased
3-fold for NTHi and even 5-fold for Mrc (Fig. 1B). Although the
bacterial MV release by Psa initially did not seem to be affected
byNAC (Fig. 1A), when the percentagewas adjusted for the num-
ber of bacteria the MV release was found to be increased 5-fold.
Overall this suggests that although NAC significantly inhibited
bacterial growth of these Gram-negative bacteria, the release of
MVs per bacterium seemed to be increased in the presence of
NAC. The release of MVs by Spn tended to decrease upon treat-
ment and disappeared when adjustments for the total bacterial
numbers were made suggesting that this decrease was the con-
sequence of the reduced number of bacteria (Fig. 1A).
The effects of NAC on bacterial growth during infection
As bacterial infections of the airways are associated with promi-
nent activation of alveolar macrophages, we examined the ef-
fects of NAC treatment on bacterial survival and MV release in
an in vitro infection model (Martin and Frevert 2005). First, we
determined bacterial growth and adhesion/internalization af-
ter macrophage infection with either one of the bacteria, and
determined how this was affected by 25 mM NAC. NAC treat-
ment almost completely prevented bacterial growth and adhe-
sion/internalization of NTHi and Mrc (Fig. 2A and B). Treatment
of Psa-infected macrophages had inconsistent effects on the
bacterial growth and hardly affected adhesion/internalization
(Fig. 2A and B). Finally, treatment of Spn led to a ∼50% re-
duction of the bacterial growth but did not affect the adher-
ence/internalization (Fig. 2A and B).
The effect of NAC on the release of bacterial and host
cell-derived MVs during macrophage infection
Next, we studied if bacterial MV shedding during macrophage
infection was affected by NAC. In the first set of experiments,
tunable resistive pulse sensing was used to quantify MVs in a
bacterial monoculture. However, during infection the MV pop-
ulation released consisted of both bacterial and host-cell MVs.
Therefore, a bead-based flow-cytometry assay for the semiquan-
titative determination of MVs was applied here. Unfortunately,
we failed to establish this platform for Spn sowe could not quan-
tify the vesicle release for this species in this setting.
At a concentration of 25 mM, NAC increased the MV release
by NTHi andMrc (Fig. 3A). When adjustments weremade for the
total number of bacteria, this increase was 5-fold for NTHi and
10-fold for Mrc (p ≤ 0.05 vs control, Fig. 3B). Regarding Psa, when
adjustments were made, the MV release was found to increase
on treatment with 25 mM NAC (Fig. 3B).
MV shedding during infection is a dynamic process that oc-
curs by both bacteria and the host. As it has been shown pre-
viously that host cell-derived MVs also have immunostimula-
tory properties (Qazi et al. 2010; Kulshreshtha et al. 2013; Soni
et al. 2016), we additionally determined the effect of NAC on the
release of CD63+/CD81+ MVs by macrophages. Treatment with
25 mM NAC significantly reduced the release of host-derived
vesicles by macrophages, irrespective of the bacteria they were
infected with (Fig. 4).
The proinflammatory response to MVs is reduced by
NAC
In earlier experiments, we demonstrated that bacterial MVs
induce the release of proinflammatory cytokines by naı̈ve
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Figure 2. The effect of NAC on bacterial survival and adhesion and internalization of respiratory pathogens during macrophage infection. Bacterial survival (A) and
adhesion/internalization (B) were determined after 4 h of infection with NTHi, Mrc, Spn and Psa without or with 25 mM NAC. Bacteria were quantified by plating and
the counts are expressed as percentage of the untreated control (n = 3, ∗P < 0.05).
Figure 3. Bacterial MV release by respiratory bacteria during infection without or with 25 mM NAC. The bacterial MV release after 4 h of infection in the presence 25
mM NAC or under control conditions was determined by bead-based flow cytometry. The relative counts are presented here as a percentage of the untreated control
(A). Moreover, the release was adjusted for the total number of bacteria present (B) (n = 3, ∗P < 0.05).
macrophages. Here, we determined if this proinflammatory re-
sponse induced by MVs from NTHi, Mrc, Spn and Psa was af-
fected by NAC treatment. As shown in Fig. 5A, all MV popula-
tions except those of Spn induced the release of TNF-α by naive
macrophages, albeit with different potencies. The response of
macrophages toMVswas dose dependently reduced in the pres-
ence of NAC for all conditions except for Spn. Importantly, we
determined that this decreased release of TNF-α was not the re-
sult of a treatment-induced cytotoxicity as NAC treatment was
not found to have cytotoxic effects (Fig. 5B). Interestingly, MVs
from NTHi and Mrc showed to have cytotoxic effects that could
be prevented by NAC treatment.
DISCUSSION
NAC is best known for its mucolytic properties, and because
of its additional antioxidant and anti-inflammatory properties,
it is an attractive drug in COPD therapy (van Overveld et al.
2005; Poole 2006; Sadowska et al. 2006; Cazzola et al. 2015; Poole,
Chong and Cates 2015). Moreover, bacteriostatic characteris-
tics have been assigned to NAC in several studies (Riise et al.
2000; Olofsson, Hermansson and Elwing 2003; Huynh et al. 2004;
Hafez et al. 2009; Zhao and Liu 2010). In this study, we con-
firmed this bacteriostatic effect as the growth of several respi-
ratory pathogens was markedly inhibited by NAC. Therefore, as
many exacerbations result from bacterial infections, the ther-
apeutic effect of NAC may be beyond its mucolytic and anti-
inflammatory and anti-oxidative properties. Additionally, in this
study we demonstrate that NAC, despite an enhancement of the
release of proinflammatory MVs by the Gram-negative bacteria
used in this study, suppressed the release of inflammatory cy-
tokines by naive macrophages in response to these MVs.
There is a great demand for new treatments that relieve air-
way obstruction and inflammatory processes in patients with
COPD (Barnes 2003). Treatment with mucolytics, most promi-
nently NAC, has been shown to alleviate these symptoms (Caz-
zola et al. 2015; Poole, Chong and Cates 2015). Moreover, (part
of) these patients frequently suffer from severe exacerbations
which are mostly caused by respiratory infections. Recently,
Cazzola et al. (2015) concluded from their meta-analysis that pa-
tients with COPD or bronchitis who received oral NAC treatment
had a decreased risk of exacerbations, although higher doses
were required in patients with airway obstruction. There are in-
dications that this protective effect of NAC may not only rely on
itsmucolytic, anti-oxidant or anti-inflammatory effects, but also
on its antibacterial activity. One study by Riise et al. (1994) shows
that COPD patients who received oral NAC therapy had a signifi-
cant reduction of the intrabronchial bacterial numbers. This an-
tibacterial activity has already been demonstrated in the 1970s
by Parry and Neu (1977), who demonstrated that NAC inhib-
ited the growth of both Gram-negative and Gram-positive bacte-
ria. Likewise, we also found that NAC caused a dose-dependent
growth reduction of all bacteria tested. Also, during infection of
naive macrophages, survival of NTHi and Mrc was significantly
reduced in the presence of NAC. Adhesion of these two Gram-
negative bacteria was markedly diminished by NAC. This is in
accordance by findings by others, who also demonstrated that
the presence of NAC significantly reduced the ability of Spn,
NTHi or Psa to adhere to epithelial cells, in vitro (Niederman et al.
1983; Zheng et al. 1999; Riise et al. 2000; Olofsson, Hermansson
and Elwing 2003; Hafez et al. 2009). These data suggest a possible
role for NAC beyond its well-known effects.
The release of MVs, which have been shown to be im-
portant vehicles for the simultaneous delivery of many ef-
fector molecules to host cells, is a common feature for both
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Figure 4. MV release by macrophages after infection with either one of the res-
piratory pathogens in the presence or absence of 25 mM NAC. The release of
CD63+/CD81+ MVs by macrophages after 4 h of infection with either one of the
bacteria (multiplicity of infection of 10) in the presence or absence of 25 mM
NAC was determined by bead-based flow cytometry. The relative counts are ex-
pressed here as a percentage of the untreated control (n = 3, ∗P < 0.05).
Figure 5. The effect of NAC on the TNF-α response by naive macrophages af-
ter stimulation with bacterial MVs. Macrophages were exposed to bacterial MVs
without or in the continuous presence of NAC (0.005, 5 or 25 mM) overnight,
where after the release of TNF-α was determined (data for Mrc-, Psa-, and Spn-
MVs are plotted on the right y-axis) (A). The cell viability after overnight MV
exposure and/or NAC treatment was determined by a MTT assay (B). The results
are presented as the mean ± SEM (n = 3, ∗P < 0.05).
Gram-negative and Gram-positive bacteria (Brown et al. 2015;
Schwechheimer and Kuehn 2015). MVsmay influence the course
of infection and the host immune response by presenting
pathogen-associated molecular patterns and antigens to their
respective host receptors. A potential involvement of bacterial
MVs in the pathogenesis of lung disease is indicated by several
studies that demonstrate that bacterial MVs are present in in-
fected tissues (Bauman and Kuehn 2006; Perez Vidakovics et al.
2010; Ren et al. 2012). Moreover, it has been demonstrated that
bacterial MVs are well able to activate immune cells and induce
the release of proinflammatory cytokines. Additionally, bacte-
rial MVs have been shown to facilitate replication of Legionella
pneumophilia in infected macrophages or to induce emphysema
via IL-17A-mediated neutrophilic inflammation (Kim et al. 2015;
Jung et al. 2016). Thus, inhibition of bacterialMV releasemight be
beneficial for the course of pulmonary disease associated with
infection (and other infection-related diseases). Here we exam-
ined the effects of NAC on the release of MVs by common respi-
ratory pathogens.We provide evidence that treatmentmarkedly
enhanced the release of these vesicles by all Gram-negative
bacteria when corrected for the number of bacteria. In contrast,
no effects on the MV release by the Gram-positive Spn were
observed.
The proposed mechanism by which NAC inhibits bacterial
growth is by inhibiting the cysteine utilization by bacteria (Parry
and Neu 1977). Additionally, thismay also explain howNAC trig-
gers the release of MVs as a recent study showed that the inhi-
bition of cysteine utilization in Neisseria meningitis cultures had
bacteriostatic effects and promoted the release of bacterial MVs
(van deWaterbeemd et al. 2013). That the bacteriostatic effects of
NAC are likely due to the inhibition of cysteine utilization might
also explain the species-specific effects observed. Since the cys-
teine requirements differ among bacteria and can even vary be-
tween strains, these differences may affect the bacterial sensi-
tivity to NAC (Guédon and Martin-Verstraete 2006).
We also showed that particularly MVs from the Gram-
negative bacteria stimulated the release of TNF-α by naive
macrophages. This is in accordance with earlier studies demon-
strating aMV-induced release of proinflammatory cytokines and
chemokines in vitro as a well as in vivo (Bauman and Kuehn 2006;
Schaar et al. 2011; Sharpe, Kuehn andMason 2011; Lee et al. 2012;
Park et al. 2013). Thus, in view of the enhanced release of MVs
by our Gram-negative bacteria, the therapeutic potential of NAC
may be limited as it may hereby enhance the pulmonary inflam-
mation. However, when we stimulated naive macrophages with
bacterial MVs, the release of TNF-α could be dose-dependently
inhibited by increasing concentrations of NAC. This suggests
that NAC might be able to counteract its proinflammatory ef-
fect due to the enhanced bacterial MV release by inhibiting the
subsequent release of proinflammatory cytokines by activated
immune cells. Additional studies are warranted to further ex-
amine the net effect of NAC in pulmonary bacterial infections.
Although several in vitro studies have shown that NAC has
potent anti-oxidant and anti-inflammatory (as reviewed by
Sadowska, Manuel-Y-Keenoy and De Backer 2007), as well as
bacteriostatic properties (Parry and Neu 1977; Riise et al. 2000;
Olofsson, Hermansson and Elwing 2003; Huynh et al. 2004; Hafez
et al. 2009; Zhao and Liu 2010), this wasmostly at concentrations
which are hard to achieve by oral administration. For example,
upon oral administration of 600 mg thrice daily for 5 days, NAC
could not be detected in the epithelial lining fluid, bronchoalve-
olar lavage fluid or lung tissue (Cotgreave et al. 1987; Bridgeman
et al. 1994). Yet, for certain respiratory conditions, such as idio-
pathic pulmonary fibrosis and cystic fibrosis, NAC is adminis-
tered by nebulization (350 mg, twice daily), whereby a high local
bioavailability is reached (Homma et al. 2012; Tam et al. 2013). In
view of the present data, which suggest that COPD patients may
also benefit from high local NAC concentrations, nebulization
might form an attractive alternative in the treatment of these
patients.
To summarize, in the current study we demonstrated that
high NAC concentrations exert bacteriostatic effects on NTHi,
Mrc, Spn and Psa cultures and on NTHi and Mrc during
macrophage infection. On the other hand, this inhibition of the
bacterial growth was accompanied by an increased MV release.
However, as our results also show that NAC markedly reduces
the proinflammatory response to MVs, it is likely that the in-
creased MV release is of little consequence. This may implicate
that NAC administration by nebulization may have a positive
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treatment outcome during airway infections, such as bacterial
exacerbations of COPD, but only when administered at a high
concentration. Future research will be required to study these
effects in vivo and to determine the long-term effects of NAC
treatment on respiratory infections and exacerbations.
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